Virpax Pharmaceuticals 将来の成長

Future 基準チェック /06

Virpax Pharmaceuticals は収益が増加すると予測されています。EPS は、年間増加すると予測されています48.7%。

主要情報

1.9%

収益成長率

48.7%

EPS成長率

Pharmaceuticals 収益成長	23.8%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	09 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqCM:VRPX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-9	N/A	N/A	1
12/31/2025	N/A	-8	N/A	N/A	1
12/31/2024	N/A	-11	N/A	N/A	1
9/30/2024	N/A	-13	-17	-17	N/A
6/30/2024	N/A	-17	-15	-15	N/A
3/31/2024	N/A	-17	-16	-16	N/A
12/31/2023	N/A	-15	-10	-10	N/A
9/30/2023	N/A	-14	-8	-8	N/A
6/30/2023	N/A	-15	-11	-11	N/A
3/31/2023	N/A	-18	-14	-14	N/A
12/31/2022	N/A	-22	-18	-18	N/A
9/30/2022	N/A	-23	-21	-21	N/A
6/30/2022	N/A	-18	-20	-20	N/A
3/31/2022	N/A	-15	-18	-18	N/A
12/31/2021	N/A	-12	-15	-15	N/A
9/30/2021	N/A	-9	-10	-10	N/A
6/30/2021	N/A	-7	-6	-6	N/A
3/31/2021	N/A	-6	-4	-4	N/A
12/31/2020	N/A	-4	-1	-1	N/A
9/30/2020	N/A	-4	-2	-2	N/A
6/30/2020	N/A	-4	-1	-1	N/A
3/31/2020	N/A	-3	-1	-1	N/A
12/31/2019	N/A	-3	-1	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VRPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VRPX今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: VRPX今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: VRPXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: VRPX来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VRPXの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Virpax Pharmaceuticals 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Recent updates

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $5.041561 million.

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Receives A Delist Determination Letter from the Listing Qualifications Department of the Nasdaq Stock Market

High number of new and inexperienced directors

Nasdaq Grants Extension Through September 30 to Virpax Pharmaceuticals to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price

New major risk - Revenue and earnings growth

Less than half of directors are independent

Virpax Pharmaceuticals, Inc. Announces the Changes to Its Board of Directors

Virpax Pharmaceuticals Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

New major risk - Shareholder dilution

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 29, 2024

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $2.25 million.

Virpax Pharmaceuticals, Inc. Announces Results of Maximum Tolerated Dose Study for Probudur

Virpax Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

Virpax Pharmaceuticals Receives Non-Compliance Letter from Nasdaq Related to Listing Rule 5550(b)(1)

New major risk - Financial position

Virpax Pharmaceuticals Regains Compliance with Listing Rule 5550(a)(2)

Price target decreased by 50% to US$2.00

Price target decreased by 50% to US$2.00

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. Announces CEO Changes

Virpax Pharmaceuticals, Inc. announced delayed 10-Q filing

Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review

Nasdaq Grants Virpax Pharmaceuticals’ Request for 180-Day Extension to Regain Compliance with the Minimum Bid Price Requirement

Novvae Pharmaceuticals Announces Executive Appointments

Virpax Pharmaceuticals, Inc Announces the Formation of Novvae™ Pharmaceuticals

Virpax Pharmaceuticals, Inc. Announces Update on Litigation

Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method

New major risk - Market cap size

Virpax Pharmaceuticals, Inc. Announces CFO Changes

New minor risk - Share price stability

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 24, 2023

Virpax Pharmaceuticals, Inc. Appoints Barbara Ruskin as Class I Director

Virpax Pharmaceuticals, Inc. Announces Positive Preclinical Toxicology Results in Support of Molecular Envelope Technology

Virpax Pharmaceuticals Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

Virpax Pharmaceuticals, Inc. Reports on FDA Pre-IND Response for NobrXiol™ (Formerly Vrp324)

Virpax Pharmaceuticals GAAP EPS of -$0.50 misses by $0.06

Virpax Pharmaceuticals, Inc. Pursues OTC Medical Device Pathway for AnQlar

Virpax Pharmaceuticals, Inc Will Pursue Direct to OTC Pathway for Epoladerm™ for Pain Associated with Osteoarthritis

Virpax Pharmaceuticals, Inc., Annual General Meeting, Jul 25, 2022

Chairman & CEO recently bought US$102k worth of stock

Virpax Pharmaceuticals, Inc. Completes Initial Preclinical Studies for VRP324

Virpax Pharmaceuticals, Inc. Reports Favorable Preclinical Safety Data for Envelta™ for the Treatment of Acute and Chronic Pain

Virpax Pharmaceuticals, Inc. Successfully Completes Preclinical Dermal Safety Studies for Epoladerm

Virpax Pharmaceuticals, Inc. Announces Clinical Trial Site in Canada for First in Human Study of Epoladerm for Pain Associated with Osteoarthritis of Knee

Virpax Pharmaceuticals, Inc. Reports Successful Results of Toxicology and Pharmacokinetic Study for Epoladerm™

Chairman & CEO recently bought US$100k worth of stock

Virpax Pharmaceuticals, Inc. (NasdaqCM:VRPX) acquired Exclusive worldwide rights of Nanomerics Ltd.

Virpax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $40.02 million.

Virpax: Targeting Pain At Its Source

Virpax Pharmaceuticals, Inc Announces That the Investigational New Drug Application Enabling Studies for Envelta

Virpax Pharmaceuticals shares surge on Envelta IND update

Virpax(R) Pharmaceuticals Inc., Virpax Begins Ind Enabling Studies of Envelta(Tm)

Virpax Pharmaceuticals, Inc. has completed an IPO in the amount of $18 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘